Krystal Biotech (NASDAQ: KRYS) closed at $317.97 on Friday, a new 52-week high, as trailing diluted EPS growth exceeding 80% confirmed that the company's topical gene therapy for recessive dystrophic epidermolysis bullosa has transitioned into a commercially viable, scaling product.

 

Key Highlights

 

  • KRYS stock declined 1.11% on the session but registered a new intraday 52-week high, with a $9.37 billion market cap reflecting strong long-term investor conviction in its gene therapy franchise.
  • Trailing diluted EPS of $7.48 has grown by more than 80% year-on-year, making Krystal Biotech one of the few profitable commercial-stage gene therapy companies listed on US exchanges.

 

Krystal Biotech stock occupies a rare position in the gene therapy sector: it generates meaningful per-share earnings from a commercial product rather than relying entirely on pipeline promise. Vyjuvek, its topical redosable gene therapy for epidermolysis bullosa, has achieved a level of commercial penetration that has consistently exceeded consensus estimates since its initial launch.

 

The company's manufacturing approach, based on a proprietary herpes simplex virus vector platform, gives it production scale advantages over competitors who rely on viral vector technologies with higher per-dose manufacturing costs. This cost structure supports the gross margins necessary to sustain profitability as the company invests in label expansion and pipeline development.

 

For investors evaluating KRYS stock as a gene therapy investment in 2026, the profitability distinction is critical. Most gene therapy stocks carry pre-commercial risk profiles; Krystal's demonstrated EPS generation removes the near-term funding uncertainty that weighs on clinical-stage peers.

 

Best biotech stocks for 2026 combining profitability with pipeline optionality include Krystal among the top tier, particularly given the company's exploration of the same delivery platform for respiratory and other dermatological conditions.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.